Progressive Myoclonus Epilepsy is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Progressive Myoclonus Epilepsy (PME) refers to a group of rare genetic disorders characterized by myoclonic seizures, progressive neurological deterioration, and typically normal or near-normal cognition in the early stages. These conditions represent a heterogeneous group of diseases with overlapping clinical features but distinct genetic etiologies.
¶ Classification and Etiology
| Disorder |
Gene/Protein |
Inheritance |
Key Features |
| Lafora disease |
EPM2A, NHLRC1 |
Autosomal recessive |
Early onset, rapid progression, death within 10 years |
| Unverricht-Lundborg disease |
CSTB |
Autosomal recessive |
Early teens onset, relatively benign course |
| Myoclonus epilepsy with ragged-red fibers (MERRF) |
MT-TK |
Mitochondrial |
Myoclonus, ataxia, sensorineural hearing loss |
| Neuronal ceroid lipofuscinosis (Batten disease) |
Multiple |
Autosomal recessive |
Childhood onset, visual loss, dementia |
| Sialidosis |
NEU1 |
Autosomal recessive |
Cherry-red spot myoclonus syndrome |
- Prevalence: Rare, estimated 1-2 per 100,000 for most forms
- Age of onset: Varies by subtype; typically childhood or adolescence
- Geographic clusters: Higher incidence of Unverricht-Lundborg in Finland and Mediterranean regions
- Lafora disease: Mutations in EPM2A (laforin) or NHLRC1 (malin) lead to abnormal glycogen metabolism
- Abnormal glycogen accumulation: Progressive intracellular glycogen accumulation in neurons, astrocytes, and peripheral tissues
- Lafora bodies: Abnormal glycogen inclusions that disrupt cellular function
- Protein aggregation: Similar mechanisms to other protein aggregation disorders (Alzheimer's, Parkinson's)
- ER stress: Endoplasmic reticulum stress response activation
- Autophagy impairment: Defective clearance of abnormal proteins
- Oxidative stress: Increased reactive oxygen species and mitochondrial dysfunction
- Glutamate dysregulation: Altered excitatory neurotransmission
- Ion channel dysfunction: Mutations affecting sodium and calcium channels
- Impaired GABAergic inhibition: Reduced inhibitory control contributing to seizures
- EPM2A gene: Encodes laforin, a glycogen phosphatase
- NHLRC1 gene: Encodes malin, an E3 ubiquitin ligase
- Dysfunctional glycogen metabolism: Abnormal branching leads to insoluble polyglucosan accumulation
- CSTB gene: Cystatin B, a cysteine protease inhibitor
- Loss of neuronal inhibition: Abnormal dendritic morphology and synaptic plasticity
- Microglial activation: Neuroinflammatory components
- Character: Lightning-like, arrhythmic, focal or generalized
- Triggering factors: Photosensitivity, stress, voluntary movement (action myoclonus)
- Progression: Initially focal, becomes generalized over time
- Impact: Severe disability due to constant jerking
- Types: Generalized tonic-clonic, absence, atonic
- Frequency: Increases with disease progression
- Status epilepticus: Common in later stages
- Ataxia: Progressive cerebellar ataxia
- Dementia: Cognitive decline in later stages
- Dysarthria: Slurred speech
- Dysphagia: Difficulty swallowing
- Early onset (6-15 years)
- Rapid cognitive decline
- Visual disturbances
- Typical death within 10 years of onset
- Onset at 6-15 years
- Relatively stable or slowly progressive
- Myoclonus is predominant feature
- Near-normal lifespan possible
- Myoclonus, epilepsy, ataxia, ragged-red fibers
- Sensorineural hearing loss
- Lactic acidosis
- Exercise intolerance
- Detailed history: Age of onset, seizure types, progression
- Neurological examination: Document myoclonus, ataxia, cognitive status
- Family history: Pattern of inheritance
- Background slowing: Progressive
- Epileptiform discharges: Generalized spike-wave, polyspike-wave
- Photosensitivity: Common in Unverricht-Lundborg
- Myoclonus correlate: EEG shows brief discharges correlated with myoclonic jerks
- MRI: May show cerebellar atrophy, cortical atrophy in later stages
- PET: Hypometabolism in affected brain regions
- Panel testing: Available for known PME genes
- Whole exome sequencing: For atypical cases
- Lafora bodies: Skin biopsy showing intracellular glycogen inclusions
- Enzyme assays: For specific metabolic forms
| Medication |
Notes |
| Valproic acid |
First-line, but hepatotoxicity concern |
| Clonazepam |
Effective for myoclonus |
| Piracetam |
Specific anti-myoclonic effect |
| Levetiracetam |
Growing evidence |
| Perampanel |
AMPA antagonist |
- Physical therapy: Maintain mobility, prevent contractures
- Occupational therapy: Adaptive devices
- Speech therapy: For dysarthria
- Nutritional support: For dysphagia
- Gene therapy: Under investigation
- Enzyme replacement: For accessible forms
- Small molecule therapies: Under development
- Rapid progression
- Mean survival: 10-15 years after onset
- Death typically in early adulthood
- Slow progression
- Variable life expectancy
- Many live into adulthood with disability
- Variable course
- Typically progressive
- Multi-system involvement
PME disorders share mechanisms with major neurodegenerative diseases:
- Protein aggregation: Similar to Alzheimer's tau and α-synuclein
- Glycogen metabolism: Links to glycogen storage diseases
- Autophagy impairment: Common to many neurodegenerative conditions
- ER stress: Shared with Parkinson's and ALS
Study of PME provides insights into:
- Protein clearance mechanisms
- Glycogen metabolism in neurons
- Neurodegeneration cascades
- Novel therapeutic targets